EP3515408A1 — Stable compositions for incretin mimetic compounds
Assigned to Delpor Inc · Expires 2019-07-31 · 7y expired
What this patent protects
A composition comprising an aqueous suspension comprising an incretin mimetic and an organic acid is described. The organic acid is one that (i) has a water solubility at room temperature of between about 0.01 and 10 g/L, (ii) has a molar mass of less than about 500 grams per mol…
USPTO Abstract
A composition comprising an aqueous suspension comprising an incretin mimetic and an organic acid is described. The organic acid is one that (i) has a water solubility at room temperature of between about 0.01 and 10 g/L, (ii) has a molar mass of less than about 500 grams per mole, and/or (iii) maintains a pH of the suspension in its environment of use of between 3.0-6.0 for a period of at least about 30 days, and stabilizes the incretin mimetic to provide a composition that is suitable for delivering the compound in a biologically active or potent form for a sustained period of time. Devices comprising the compositions and methods of treatment are also described.
Drugs covered by this patent
- Ozempic (semaglutide) · Novo Nordisk
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.